Abdel-Rahman Omar, Fouad Mona
Faculty of Medicine, Clinical Oncology Department, Ain Shams University, Cairo, Egypt.
Expert Rev Anticancer Ther. 2015 Apr;15(4):465-75. doi: 10.1586/14737140.2015.1014035. Epub 2015 Feb 9.
We performed a meta-analysis of diarrhea and stomatitis associated with erlotinib use in patients with advanced non-small cell lung cancer. Eligible studies included randomized trials of patients with non-small cell lung cancer on erlotinib describing events of diarrhea and stomatitis. A total of 19 clinical trials including 7524 patients were considered eligible for the meta-analysis. The relative risk of all-grade diarrhea and stomatitis were 2.96 (95% CI: 2.31-3.8; p < 0.00001), 3.62 (95% CI: 2.43-5.39; p = 0.00001), respectively, whereas the relative risk of high-grade diarrhea and stomatitis were 4.65 (95% CI: 3.30-6.55; p < 0.00001), 2.63 (95% CI: 0.83-8.27; p = 0.1), respectively. Our meta-analysis has demonstrated that regimens containing erlotinib for the treatment of advanced non-small cell lung cancer are associated with a significantly increased risk of all-grade diarrhea, stomatitis and high-grade diarrhea. Close clinical monitoring is required when using and administering this drug.
我们对晚期非小细胞肺癌患者使用厄洛替尼相关的腹泻和口腔炎进行了一项荟萃分析。符合条件的研究包括针对使用厄洛替尼的非小细胞肺癌患者的随机试验，这些试验描述了腹泻和口腔炎事件。共有19项临床试验（包括7524例患者）被认为符合荟萃分析的条件。所有级别的腹泻和口腔炎的相对风险分别为2.96（95%CI：2.31 - 3.8；p < 0.00001）、3.62（95%CI：2.43 - 5.39；p = 0.00001），而重度腹泻和口腔炎的相对风险分别为4.65（95%CI：3.30 - 6.55；p < 0.00001）、2.63（95%CI：0.83 - 8.27；p = 0.1）。我们的荟萃分析表明，含厄洛替尼的方案用于治疗晚期非小细胞肺癌与所有级别腹泻、口腔炎及重度腹泻的风险显著增加相关。使用和给药该药物时需要密切的临床监测。
